MYGN

Myriad Genetics Inc

MYGN, USA

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The co

https://www.myriad.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MYGN
stock
MYGN

Myriad Genetics, Inc. $MYGN Stake Reduced by Camber Capital Management LP MarketBeat

Read more →
MYGN
stock
MYGN

Discipline and Rules-Based Execution in MYGN Response news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$8.3818

Analyst Picks

Strong Buy

3

Buy

3

Hold

6

Sell

2

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-7.35 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.76 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Low

7.24 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

0.95

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 99.05% of the total shares of Myriad Genetics Inc

1.

BlackRock Inc

(16.199%)

since

2025/06/30

2.

Vanguard Group Inc

(9.9495%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.8934%)

since

2025/08/31

4.

Millennium Management LLC

(5.2929%)

since

2025/06/30

5.

State Street Corp

(5.1695%)

since

2025/06/30

6.

Glenview Capital Management LLC

(4.9303%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(4.8945%)

since

2025/06/30

8.

D. E. Shaw & Co LP

(4.8487%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.8536%)

since

2025/07/31

10.

Geode Capital Management, LLC

(2.3891%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(2.3513%)

since

2025/08/31

12.

Dimensional Fund Advisors, Inc.

(2.2282%)

since

2025/06/30

13.

Qube Research & Technologies

(2.205%)

since

2025/06/30

14.

Camber Capital Management LLC

(2.1495%)

since

2025/06/30

15.

Citadel Advisors Llc

(1.8389%)

since

2025/06/30

16.

Connor Clark & Lunn Inv Mgmt Ltd

(1.4916%)

since

2025/06/30

17.

SPDR® S&P Biotech ETF

(1.4789%)

since

2025/08/31

18.

Anson Funds Management LP

(1.447%)

since

2025/06/30

19.

Charles Schwab Investment Management Inc

(1.4359%)

since

2025/06/30

20.

Fisher Asset Management, LLC

(1.3916%)

since

2025/06/30

21.

Goldman Sachs Group Inc

(1.3794%)

since

2025/06/30

22.

Kent Lake PR LLC

(1.3434%)

since

2025/06/30

23.

Portolan Capital Management, LLC

(1.2504%)

since

2025/06/30

24.

Federated Hermes Inc

(1.2062%)

since

2025/06/30

25.

Vanguard Small Cap Index

(1.1417%)

since

2025/07/31

26.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0801%)

since

2025/07/31

27.

Federated Hermes MDT Small Cap Core IS

(1.0797%)

since

2025/06/30

28.

Federated Hermes MDT SCC Institutional

(1.0797%)

since

2025/06/30

29.

abrdn Healthcare Opportunities

(1.0233%)

since

2025/07/31

30.

Fidelity Small Cap Index

(0.9825%)

since

2025/06/30

31.

iShares S&P Small-Cap 600 Value ETF

(0.9213%)

since

2025/08/31

33.

iShares Russell 2000 Value ETF

(0.854%)

since

2025/08/31

34.

Disciplined Growth - Mid Cap Growth

(0.7689%)

since

2024/12/31

35.

Vanguard Small Cap Value Index Inv

(0.733%)

since

2025/07/31

36.

Vanguard Strategic Equity Inv

(0.6967%)

since

2025/06/30

37.

iShares Biotechnology ETF

(0.568%)

since

2025/08/31

38.

UBS (Irl) Inv Sel Glb Eq L/S IA1 PF

(0.5574%)

since

2025/03/31

39.

SPDR® S&P 600 Small Cap Value ETF

(0.5469%)

since

2025/08/31

40.

Vanguard Tax-Managed Small Cap Adm

(0.5367%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.0018

Latest Release

Date

2025-09-30

EPS Actual

-0.2943

EPS Estimate

-0.0132

EPS Difference

-0.2811

Surprise Percent

-2129.5455%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(3.5)
Quality
Moderate Quality(4)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.